The second year of the COVID-19 pandemic has demonstrated the need for detection and assessment of the long-term consequences SARS-CoV-2 infection, including adequate cognitive functioning. This review addresses our current understanding of the direct and indirect mechanisms of nervous system infection in COVID-19, paying special attention to cause-effect relationships between SARS-CoV-2 infection and long-term neuropsychological disorders. Understanding the pathogenesis of neurological impairments in COVID-19 is important for studies of the long-term sequelae of the disease and for identifying preventive and therapeutic possibilities in relation to brain damage. Further studies of nervous system lesions in COVID-19 are clearly needed to expand existing knowledge. Early initiation of therapeutic measures for emerging disorders will probably have decisive importance for improving quality of life for many COVID-19 survivors.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
A. Yassin, M. Nawaiseh, A. Shaban, et al., “Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis,” BMC Neurol., 21, No. 1, 138 (2021), 10.1186/s12883-021-02161-4.
A. Nalbandian, K. Sehgal, A. Gupta, et al., “Post-acute COVID-19 syndrome,” Nat. Med., 27, No. 4, 601–615 (2021), https://doi.org/10.1038/s41591-021-01283-z.
Y. M. J. Goërtz, M. Van Herck, J. M. Delbressine, et al., “Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?” ERJ Open Res., 6, No. 4, 00542–2020 (2020), https://doi.org/10.1183/23120541.00542-2020.
H. Akbarialiabad, M. H. Taghrir, A. Abdollahi, et al., “Long COVID, a comprehensive systematic scoping review,” Infection, 28, 1–24 (2021), https://doi.org/10.1007/s15010-021-01666-x.
L. Sigfrid, T. M. Drake, E. Pauley, et al., “Long covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol,” Lancet Regional Health Eur., 8, 100186 (2021), https://doi.org/10.1016/j.lanepe.2021.100186.
A. Carfì, R. Bernabei, and F. Landi, “Persistent symptoms in patients after acute COVID-19,” JAMA, 324, No. 6, 603–605 (2020), https://doi.org/10.1001/jama.2020.12603.
Z. Al-Aly, Y. Xie, and B. Bowe, “High-dimensional characterization of post-acute sequelae of COVID-19,” Nature, 594, No. 7862, 259– 264 (2021), https://doi.org/10.1038/s41586-021-03553-9.
S. H. Chou, E. Beghi, R. Helbok, et al., “Global incidence of neurological manifestations among patients hospitalized with COVID-19 – A report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium,” JAMA Netw. Open, 4, No. 5, e2112131 (2021), https://doi.org/10.1001/jamanetworkopen.2021.12131.
J. Helms, S. Kremer, H. Merdji, et al., “Neurologic features in severe SARS-CoV-2 infection,” N. Engl. J. Med., 382, No. 23, 2268–2270 (2020), https://doi.org/10.1056/NEJMc2008597.
J. P. Rogers, E. Chesney, D. Oliver, et al., “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic,” Lancet Psychiatry, 7, No. 7, 611–627 (2020), https://doi.org/10.1016/S2215-0366(20)30203-0.
H. Zhou, S. Lu, J. Chen, et al., “The landscape of cognitive function in recovered COVID-19 patients,” J. Psychiatr. Res., 129, 98–102 (2020), https://doi.org/10.1016/j.jpsychires.2020.06.022.
H. Ali Awan, M. Najmuddin Diwan, A. Aamir, et al., “SARS-CoV-2 and the brain: What do we know about the causality of Cognitive COVID?” J. Clin. Med., 10, No. 15, 3441 (2021), https://doi.org/10.3390/jcm10153441.
A. Nalbandian, K. Sehgal, A. Gupta, et al., “Post-acute COVID-19 syndrome,” Nat. Med., 27, No. 4, 601–615 (2021), https://doi.org/10.1038/s41591-021-01283-z.
M. Taquet, J. R. Geddes, M. Husain, et al., “6-Month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health records,” Lancet Psychiatry, 8, No. 5, 416–427 (2021), https://doi.org/10.1016/S2215-0366(21)00084-5.
A. Jaywant, W. M. Vanderlind, G. S. Alexopoulos, et al., “Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19,” Neuropsychopharmacology, 15, 1–6 (2021), https://doi.org/10.1038/s41386-021-00978-8.
A. Hampshire, W. Trender, S. Chamberlain, et al., “Cognitive deficits in people who have recovered from COVID-19,” EClinical-Medicine, 39, 101044 (2021), https://doi.org/10.1016/j.eclinm.2021.101044.
M. S. Woo, J. Malsy, J. Pöttgen, et al., “Frequent neurocognitive deficits after recovery from mild COVID-19,” Brain Commun., 2, No. 2, fcaa205 (2020), https://doi.org/10.1093/braincomms/fcaa205.
S. Dubey, P. Biswas, R. Ghosh, et al., “Psychosocial impact of COVID-19,” Diabetes Metab. Syndr., 14, No. 5, 779–788 (2020), https://doi.org/10.1016/j.dsx.2020.05.035.
S. N. Mosolov, “Mental health problems in the COVID-19 pandemic,” Zh. Nevrol. Psikhiatr., 120, No. 5, 7–15 (2020), 10.17116/jnevro20201200517.
A. Cagnin, R. Di Lorenzo, C. Marra, et al., “Behavioral and psychological effects of coronavirus disease-19 quarantine in patients with dementia,” Front. Psychiatry, 11, 578015 (2020), https://doi.org/10.3389/fpsyt.2020.578015.
G. Cohen, M. J. Russo, J. A. Campos, and R. F. Allegri, “COVID-19 epidemic in Argentina: Worsening of behavioral symptoms in elderly subjects with dementia living in the community,” Front. Psychiatry, 11, 866 (2020), https://doi.org/10.3389/fpsyt.2020.00866.
G. Livingston, J. Huntley, A. Sommerlad, et al., “Dementia prevention, intervention, and care: 2020 report of the Lancet Commission,” Lancet, 396, No. 10248, 413–446 (2020), https://doi.org/10.1016/S0140-6736(20)30367-6.
E. E. Brown, S. Kumar, T. K. Rajji, et al., “Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer’s disease and related dementias,” Am. J. Clin. Geriatr. Psychiatry, 28, No. 7, 712–721 (2020), https://doi.org/10.1016/j.jagp.2020.04.010.
K. Ritchie, D. Chan, and T. Watermeyer, “The cognitive consequences of the COVID-19 epidemic: collateral damage?” Brain Commun., 2, No. 2, fcaa069 (2020), https://doi.org/10.1093/braincomms/fcaa069.
A. Cagnin, R. Di Lorenzo, C. Marra, et al., “Behavioral and psychological effects of coronavirus disease-19 quarantine in patients with dementia,” Front. Psychiatry, 11, 578015 (2020), https://doi.org/10.3389/fpsyt.2020.578015.
A. Ramani, L. Müller, P. N. Ostermann, et al., “SARS-CoV-2 targets neurons of 3D human brain organoids,” EMBO J., 39, No. 20, e106230 (2020), 10.15252/embj.2020106230.
E. Chekol Abebe, T. Mengie Ayele, Z. Tilahun Muche, and T. Asmamaw Dejenie, “Neuropilin 1: A novel entry factor for SARS-CoV-2 infection and a potential therapeutic target,” Biologics, 15, 143–152 (2021), https://doi.org/10.2147/BTT.S307352.
M. A. Erickson, E. M. Rhea, R. C. Knopp, and W. A. Banks, “Interactions of SARS-CoV-2 with the blood–brain barrier,” Int. J. Mol. Sci., 22, No. 5, 2681 (2021), 10.3390/ijms22052681.
N. K. Jha, S. Ojha, S. K. Jha, et al., “Evidence of coronavirus (CoV) pathogenesis and emerging pathogen sars-cov-2 in the nervous system: A review on neurological impairments and manifestations,” J. Mol. Neurosci., 19, 1–18 (2021), https://doi.org/10.1007/s12031-020-01767-6.
A. Al-Ramadan, O. Rabab’h, J. Shah, and A. Gharaibeh, “Acute and post-acute neurological complications of COVID-19,” Neurol. Int., 13, No. 1, 102–119 (2021), https://doi.org/10.3390/neurolint13010010.
E. Song, C. Zhang, B. Israelow, et al., “Neuroinvasion of SARSCoV-2 in human and mouse brain,” J. Exp. Med., 218, No. 3, e20202135 (2021), https://doi.org/10.1084/jem.20202135.
A. Lippi and R. Domingues, C. Setz, T. F. Outeiro, and A. Krisko, “SARS-CoV-2: At the crossroad between aging and neurodegeneration,” Mov. Disord., 35, No. 5, 716–720 (2020), https://doi.org/10.1002/mds.28084.
Y. Lu, X. Li, D. Geng, et al., “Cerebral Micro-structural changes in COVID-19 patients – An MRI-based 3-month follow-up study,” EClinicalMedicine, 25, 100484 (2020), https://doi.org/10.1016/j.eclinm.2020.100484.
Y. C. Li, W. Z. Bai, and T. Hashikawa, “The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients,” J. Med. Virol., 92, No. 6, 552–555 (2020), https://doi.org/10.1002/jmv.25728.
S. J. Yong, “Persistent brainstem dysfunction in long-COVID: A hypothesis,” ACS Chem. Neurosci., 12, No. 4, 573–580 (2021), https://doi.org/10.1021/acschemneuro.0c00793.
E. B. Mukaetova-Ladinska, G. Kronenberg, and R. Raha-Chowdhury, “COVID-19 and neurocognitive disorders,” Curr. Opin. Psychiatry, 34, No. 2, 149–156 (2021), https://doi.org/10.1097/YCO.0000000000000687.
D. Lahiri and A. Ardila, “COVID-19 pandemic: A neurological perspective,” Cureus, 12, No. 4, e7889 (2020), https://doi.org/10.7759/cureus.7889.
L. Beishon and R. B. Panerai, “The neurovascular unit in dementia: An opinion on current research and future directions,” Front. Aging Neurosci., 13, 721937 (2021), https://doi.org/10.3389/fnagi.2021.721937.
S. Miners, P. G. Kehoe, and S. Love, “Cognitive impact of COVID-19: looking beyond the short term,” Alzheimers Res. Ther., 12, No. 1, 170 (2020), https://doi.org/10.1186/s13195-020-00744-w.
C. Sasannejad, E. W. Ely, and S. Lahiri, “Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms,” Crit. Care, 23, No. 1, 352 (2019), 10.1186/s13054-019-2626-z.
A. Ardila and D. Lahiri, “Executive dysfunction in COVID-19 patients,” Diabetes Metab. Syndr., 14, No. 5, 1377–1378 (2020), https://doi.org/10.1016/j.dsx.2020.07.032.
K. Honarmand, R. S. Lalli, F. Priestap, et al., “Natural history of cognitive impairment in critical illness survivors. A systematic review,” Am. J. Respir. Crit. Care Med., 202, No. 2, 193–201 (2020), https://doi.org/10.1164/rccm.201904-0816CI.
P. P. Pandharipande, T. D. Girard, J. C. Jackson, et al., “Long-term cognitive impairment after critical illness,” N. Engl. J. Med., 369, 1306–1316 (2013), https://doi.org/10.1056/NEJMoa1301372.
C. Iadecola, J. Anrather, and H. Kamel, “Effects of COVID-19 on the nervous system,” Cell, 183, 16–27 (2020), https://doi.org/10.1016/j.cell.2020.08.028.
G. A. De Erausquin, H. Snyder, M. Carrillo, et al., “The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning,” Alzheimers Dement (NY), 17, No. 6, 1056–1065 (2021), https://doi.org/10.1002/alz.12255.
N. Moghimi, M. Di Napoli, J. Biller, et al., “The neurological manifestations of post-acute sequelae of SARS-CoV-2 infection,” Curr. Neurol. Neurosci. Rep., 21, No. 9, 44 (2021), 10.1007/s11910-021-01130-1.
O. A. Gomazkov, “Corexin: Molecular mechanisms and targets for neuroprotective Activity,” Zh. Nevrol. Psikhiatr., 115, No. 8, 99–104 (2015), 10.17116/jnevro20151158199-104.
A. A. Yakovlev, A. A. Lyzhin, L. G. Khaspekov, et al., “Peptide drug cortexin inhibits brain caspase-8,” Biomed. Khim., 63, No. 1, 27–31 (2017).
V. G. Pinelis, T. P. Storozhevykh, E. G. Sorokina, et al., “Effects of Cortexin on the survival of cultured brain neurons exposed to glutamate toxicity or deprived of growth factors,” in: Peptide Neuroprotection. A Collection of Scientifi c Reports, M. M. D’yakonov and A. A. Kamenskii (eds.), Nauka, St. Petersburg (2009).
S. I. Shram and A. V. Baibak, “Cytoprotective action of Cortexin and retinalamine in models of necrotic neuron death induced by oxidative stress,” in: Peptide Neuroprotection. A Collection of Scientifi c Reports, M. M. D’yakonov and A. A. Kamenskii (eds.), Nauka, St. Petersburg (2009).
A. A. Yakovlev and N. V. Gulyaeva, “Molecular partners of Cortexin in the brain,” Neirokhimiya, 33, No. 1, 91–96 (2017), https://doi.org/10.7868/s1027813316040166,
M. Yu. Stepanichev, M. V. Onufriev, N. A. Lazareva, et al., “Effects of the formulation Cortexin on free radical oxidation and infl ammatory processes in rats with normal and accelerated aging,” Neirokhimiya, 35, No. 2, 1–12 (2018), https://doi.org/10.7868/s1027813318020127.
N. V. Gulyaeva, “Molecular mechanisms of action of formulations containing brain peptides: Cortexin,” Zh. Nevrol. Psikhiatr., 118, No. 10, 93–96 (2018), 10.17116/jnevro201811810193.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 121, No. 10, Iss. 1, pp. 131–137, October, 2021.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Khoreva, M.A. Postcovid Syndrome – The New Reality. Neurosci Behav Physi 52, 619–624 (2022). https://doi.org/10.1007/s11055-022-01286-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-022-01286-4